Functional dyspepsia pathogenesis and therapeutic options-Implications for management

Digestive and Liver Disease

Volumn 37, Issue 8, 2005, Pages 547-558

  Smith, M Lancaster ^a  

^a QUEEN MARY S HOSPITAL   (United Kingdom)

Author keywords

Brain gut axis; Functional dyspepsia; Gastroduodenal dysfunction; H. pylori; Health seeking behaviour; Post infective; Psychosocial factors

Indexed keywords

ANTIBIOTIC AGENT; ARTICHOKE EXTRACT; ASIMADOLINE; BUSPIRONE; CAPSAICIN; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CISAPRIDE; CLONIDINE; DEXTROMETHORPHAN; DOMPERIDONE; ERYTHROMYCIN; FEDOTOZINE; HISTAMINE H2 RECEPTOR ANTAGONIST; METOCLOPRAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OPIATE AGONIST; PAROXETINE; PLACEBO; PLANT EXTRACT; PROKINETIC AGENT; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SILDENAFIL; STOMACH SECRETION INHIBITOR; SUMATRIPTAN; TACHYKININ RECEPTOR ANTAGONIST; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

ANXIETY DISORDER; ARTICHOKE; CHILD ABUSE; CHILD SEXUAL ABUSE; CLINICAL TRIAL; COGNITIVE THERAPY; COPING BEHAVIOR; CORRELATION ANALYSIS; DROWSINESS; DRUG MECHANISM; DRUG TARGETING; DUODENUM DISEASE; DYSPEPSIA; EMOTIONAL STRESS; ERADICATION THERAPY; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL INFECTION; GASTROINTESTINAL MOTILITY DISORDER; GENERAL PRACTICE; HEART ARRHYTHMIA; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HELP SEEKING BEHAVIOR; HOSTILITY; HUMAN; HYPERSENSITIVITY; HYPNOSIS; INTESTINE INNERVATION; LIFE EVENT; LOW FAT DIET; MEDICAL DECISION MAKING; MENTAL DISEASE; MORBIDITY; MUSCLE RELAXATION; NEUROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL INTOLERANCE; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT COUNSELING; PERSONALITY; QUALITY OF LIFE; SHORT SURVEY; SOCIAL PSYCHOLOGY; STOMACH ACID; STOMACH EMPTYING; STOMACH FUNDUS; STOMACH MUCOSA INJURY; WEIGHT REDUCTION; HYPERALGESIA; PERCEPTIVE THRESHOLD; PHYSIOLOGY; PHYTOTHERAPY; PSYCHOLOGICAL ASPECT; REVIEW;

COGNITIVE THERAPY; DYSPEPSIA; HUMANS; HYPERALGESIA; HYPNOSIS; NEUROTRANSMITTER AGENTS; PHYTOTHERAPY; SENSORY THRESHOLDS;

EID: 33644632422     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2005.04.001     Document Type: Short Survey

References (162)

1. Talley N.J., Stanghellini V., Heading R.C., Koch K.L., Malagelada J.R., and Tytgat G.N. Functional gastroduodenal disorders. Gut 45 Suppl. 2 (1999) 1137-1142
2. Agreus L., Svardsudd K., Nyren O., and Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 109 (1995) 671-680
3. Drossman D.A., Li Z., Andrazzi E., Temple R.D., Talley N.J., Thompson W.G., et al. US householder survey of functional gastrointestinal disorders, prevalence, sociodemography and health impact. Dig Dis Sci 38 (1993) 1569-1580
4. Jones R.H., Lydeard S.E., Hobbs F.D., Kenkre J.E., Williams E.L., Jones S.J., et al. Dyspepsia in England and Scotland. Gut 31 (1990) 401-405
5. Klauser A.G., Voderholzer W.A., Knesewitsch P.A., Schindlbeck N., and Muller-Lissner S.A. What is behind dyspepsia. Dig Dis Sci 38 (1993) 147-154
6. 2-blocker therapy or prompt endoscopy in the management of dyspepsia. Lancet 343 (1994) 811-816
7. Talley N.J., Weaver A.L., and Zinmeister A.R. Impact of functional dyspepsia on quality of life. Dig Dis Sci 40 (1995) 584-589
8. Nyren O., Lindberg G., Lindstrom E., Marke E., and Seensalu R. Economic costs of functional dyspepsia. Pharmacoeconomics 1 (1992) 312-324
9. Agreus L., and Borgquist L. The cost of gastro-oesophageal reflux disease, dyspepsia and peptic ulcer disease in Sweden. Pharmacoeconomics 20 (2002) 347-355
10. Talley N.J., Weaver A.L., Zinmeister A.R., and Mector III L.J. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemiol 136 (1992) 165-177
11. Locke G.R., Talley N.J., Carpenter H.A., Harmsen W., Zinsmeister A.R., and Melton L.J. Changes in site and histology-specific incidence of gastric cancer during a 50 year period. Gastroenterology 109 (1995) 1750-1756
12. Kay L., and Jorgensen T. Epidemiology of upper dyspepsia in a random population. Scand J Gastroenterol 29 (1994) 1-6
13. Agreus L., Svardsudd L., Nyen O., and Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 109 (1995) 671-680
14. Talley N.J., McNeil D., Hayden A., Colreavy C., and Piper D.W. Prognosis of chronic unexplained dyspepsia. Gastroenterology 92 (1987) 1060-1066
15. El Serag H.B., and Talley N.J. Systematic review: the prevalence and clinical course of functional dyspepsia. Aliment Pharmacol Ther 19 (2004) 643-654
16. Whitehead W.E., Gibbs N.A., Zhimming L., and Drossman D.A. Is functional dyspepsia just a subset of the irritable bowel syndrome?. Balliere's Clin Gastroenterol 12 (1998) 443-461
17. Quigley E.M. Functional dyspepsia and non-erosive reflux disease: overlapping or discrete entities. Best Prac Res Clin Gastroenterol 18 (2004) 695-706
18. Collin-Jones D.G., Bloom B., Bodeman G., Crean G., Freston J., Gugler R., et al. Management of dyspepsia: report of a working party. Lancet 1 (1988) 576-579
19. Talley N.J., Collin-Jones D.G., Kock K.L., Koch M., Nyren O., and Stanghellini V. Functional dyspepsia, a classification with guidelines for diagnosis and management. Gastroenterol Int 4 (1991) 145-160
20. Heading R.C. Definitions of dyspepsia. Scand J Gastroenterol 26 Suppl. 182 (1991) 1-6
21. Holtman G., Stanghellini V., and Talley N.J. Nomenclature of dyspepsia, dyspepsia subgroups and functional dyspepsia: clarifying concepts. Balliere's Clin Gastroenterol 12 (1998) 417-433
22. Talley N.J. Review article: functional dyspepsia - should treatment be targeted on disturbed physiology. Aliment Pharmacol Ther 9 (1995) 107-115
23. Collen M.J., and Loebenberg M.J. Basal gastric acid secretion in non-ulcer dyspepsia with or without duodenitis. Dig Dis Sci 34 (1989) 246-260
24. Samson M., Verhagen M.A., Van Berge Henegouwen G.P., and Smout A.J. Abnormal clearance of exogenous acid and increased sensitivity of proximal duodenum in dyspeptic patients. Gastroenterology 116 (1999) 515-520
25. Lee K.J., Vos R., Hanssens J., and Tack J. Influence of duodenal acidification on the sensori-motor function of the proximal stomach in man. Am J Physiol Gastrointest Liver Physiol 286 (2004) G278-G284
26. Schwarz M.P., Samson M., and Smout A.J. Chemospecific alterations in duodenal perception and motor response in functional dyspepsia. Am J Gastroenterol 96 (2001) 2596-2602
27. Lee K.J., Demarchi J., Vos R., Demelts I., Janssens J., and Tack J. Comparison of duodenal acid exposure in functional dyspepsia patients and healthy controls using 24 hour ambulatory duodenal pH monitoring. Gastroenterology 122 (2002) A102
28. Sarnelli G., Janssens J., and Tack J. Helicobacter pylori is not associated with symptoms and pathophysiological mechanisms of functional dyspepsia. Dig Dis Sci 48 (2003) 2229-2236
29. Danesh J., Lawrence M., Murphy M., Roberts S., and Collins R. Systematic review of the epidemiological evidence on Helicobacter pylori infection and non-ulcer and uninvestigated dyspepsia. Arch Int Med 160 (2000) 1192-1198
30. Stanghellini V., Tosetti C., Paternico A., De Giorgio R., Barbara G., Salvioli B., et al. Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology 110 (1996) 1036-1042
31. Quartero A., de Wit N.J., Lodder I.M., Numans M.E., Smout A.J., and Hoes A.W. Disturbed solid phase gastric emptying in functional dyspepsia: a meta-analysis. Dig Dis Sci 43 (1998) 2028-2033
32. Perri F., Clemente R., Festa V., Annese V., Quitadamo M., Rutgeerts P., et al. Patterns of symptoms in functional dyspepsia: role of Helicobacter pylori infection and delayed gastric emptying. Am J Gastroenterol 93 (1998) 2082-2088
33. Sarnelli G., Caenepeel P., Geypens B., Janssens J., and Tack J. Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol 98 (2003) 783-788
34. Tack J., Piessevaux H., Couli B., Caenepeel P., and Janssens J. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gut 42 (1998) 823-829
35. Salet G.A.M., Samson M., Roelofs J.M.M., Van Berge Henegouwen G.P., Smout A.J., and Akkermans L.M. Responses to gastric distension in functional dyspepsia. Gut 42 (1998) 823-829
36. Gilja O.H., Hausken T., Wilhelmsen I., and Bertrand H. Impaired accommodation of proximal stomach to a meal in functional dyspepsia. Dig Dis Sci 41 (1996) 689-696
37. Kim D.Y., Delgado-Aros S., Camilleri M., Samson M., Murray J.A., O'Connor M.K., et al. Non-invasive measurement of gastric accommodation in patients with idiopathic non-ulcer dyspepsia. Am J Gastroenterol 96 (2001) 3099-3105
38. Scott A.M., Kellow J.E., Schutter G., Cowan H., Corbett A.M., Riley J.W., et al. Intragastric disturbance and gastric emptying of solids and liquids in functional dyspepsia. Dig Dis Sci 38 (1993) 2247-2254
39. Troncon L.E.A., Bennett R.J.M., Ahluwalia N.K., and Thompson D.G. Abnormal disturbance of food during gastric emptying in functional dyspepsia patients. Gut 35 (1994) 327-332
40. Troncon L.E.A., Thompson D.G., Ahluwalia N.K., Barlow J., and Heggie L. Relations between upper abdominal symptoms and gastric distension abnormalities in dysmotility-like functional dyspepsia and after vagotomy. Gut 37 (1995) 17-22
41. Desai K.M., Sessa W.C., and Vane J.R. Involvement of nitric oxide in the reflex relaxation of the stomach to accommodation food or fluid. Nature 35 (1991) 477-479
42. Tack J., Demelts I., Dehondt G., Caenepeel P., Fischler B., Zandeki M., et al. Clinical and pathophysiological characteristics of acute onset functional dyspepsia. Gastroenterology 122 (2002) 1738-1747
43. Simnea M., Vos R., Janssens J., and Tack J. Unsuppressed post prandial phasic contrability in the proximal stomach in functional dyspepsia: relevance to symptoms. Am J Gastroenterol 98 (2003) 2169-2175
44. Bradette M., Pare P., Douville P., and Morin A. Visceral perception in health and functional dyspepsia: crossover study of gastric distension with placebo and domperidone. Dig Dis Sci 36 (1991) 52-58
45. Coffin B., Azpiroz F., Guarner F., and Malagelada J.R. Selective gastric hypersensitivity and reflux hyporeactivity in functional dyspepsia. Gastroenterology 107 (1994) 1345-1351
46. Lemann M., Dederding J.P., Flourie B., Franchisseur C., Ramband J.C., and Jian R. Abnormal perception of visceral pain in response to gastric distension in chronic idiopathic dyspepsia: the irritable stomach syndrome. Dig Dis Sci 36 (1991) 1249-1254
47. Mertz H., Fullerton S., Naliboff B., and Mayer E.A. Symptoms and visceral perception in severe functional and organic dyspepsia. Gut 42 (1998) 814-822
48. Holtmann G., Gschossmann J., Neufarg-Huber J., Gerken G., and Talley N.J. Differences in gastric mechano-sensory function after repeated ramp distensions in non-consulters with dyspepsia and healthy controls. Gut 47 (2000) 332-336
49. Tack J., Caenepeel P., Fischler B., Piessevaux H., and Janssens J. Symptoms associated with hypersensitivity to gastric distension in functional dyspepsia. Gastroenterology 121 (2001) 526-535
50. Tack J., Bisschops R., and Caenepeel P. Pathophysiological relevance of fasting versus post prandial sensitivity testing in functional dyspepsia. Gastroenterology 122 (2002) A301
51. Ford M.J., Camilleri M., Zinmeister A.R., and Hanson R.B. Psychosensory modulation of colonic sensation in the human transverse and sigmoid colon. Gastroenterology 109 (1995) 1772-1780
52. Accarino A.M., Azpiroz F., and Malagelada J.R. Attention and distraction: effects on gut perception. Gastroenterology 113 (1997) 415-422
53. Sarker S., Aziz O., Woolf C.J., Hobson A.R., and Thompson D.G. Contribution of central sensitisation to the development of non cardiac chest pain. Lancet 30 (2000) 1154-1159
54. Barbera R., Feinle C., and Read N.W. Abnormal sensitivity to duodenal lipid infusion in patients with functional dyspepsia. Eur J Gastroenterol Hepatol 7 (1995) 1051-1057
55. Feinle C., Meier O., Otto B., D'Amato M., and Frieil M. Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia. Gut 48 (2001) 347-355
56. Feinle C., and Read N.W. Ondansetron reduces nausea induced by gastroduodenal stimulation without changing gastric motility. Am J Physiol 271 (1996) G591-G597
57. Stanghellini V., Ghidini C., Maccarini M.R., Paparo G.F., Corinaldesi R., and Barbara L. Fasting and post prandial gastrointestinal motility in ulcer and non-ulcer dyspepsia. Gut 23 (1992) 184-190
58. Camilleri M., Hasler W.L., Parkman H.P., and Quigley E.M. Soffer measurement of gastrointestinal motility in the GI laboratory. Gastroenterology 115 (1998) 747-762
59. Lin W., Eaker E.Y., Sarosiek I., and McCallum R.W. Gastric myoelectrical activity and gastric emptying in patients with functional dyspepsia. Am J Gastroenterol 94 (1999) 2384-2389
60. Pfaffenbach B., Adamek R.J., Bartholomew C., and Wegener M. Gastric dysrhythmias and delayed gastric emptying in patients with functional dyspepsia. Dig Dis Sci 42 (1997) 2094-2099
61. Van Oudenhove L., Demyltenaeve K., Tack J., and Aziz Q. Central nervous system involvement in functional gastrointestinal disorders. Best Prac Res Clin Gastroenterol 18 (2004) 663-680
62. Hobson A.R., and Aziz Q. Brain imaging and functional gastrointestinal disorders: has it helped our understanding. Gut 53 (2004) 1198-1206
63. Budavari A.I., and Olden K.W. Psychosocial aspects of functional gastrointestinal disorders. Gastroenterol Clin North Am 32 (2003) 477-506
64. Castle M.Z.D., Silk D.B.A., and Libby G.W. Review article: the rationale for antidepressant therapy in functional gastrointestinal disorders. Aliment Pharmacol Ther 19 (2004) 969-979
65. Fischler B., Tack J., De Gucht V., Shkedy Z.I., and Persoons P. Heterogeneity of symptom pattern, psychosocial factors and pathophysiological mechanisms in severe functional dyspepsia. Gastroenterology 124 (2003) 903-910
66. Bennet E.J., Piesse C., Palmer K., Badcock C.A., Tennant C.C., and Kellow J.E. Functional gastrointestinal disorders, psychological, social and somatic features. Gut 42 (1998) 414-420
67. Hamilton J., Guthrie E., Creed F., Thompson D., Tomensen B., Bennett R., et al. A randomised controlled trial of psychotherapy in patients with chronic functional dyspepsia. Gastroenterology 119 (2000) 661-669
68. Calvert E.L., Houghton L.A., Cooper P., and Whorwell P. Long term improvement in functional dyspepsia using hypnotherapy. Gastroenterology 123 (2002) 1778-1785
69. Craig T.K.J., and Brown G.W. Goal frustration and life events in the aetiology of painful gastrointestinal disorders. J Psychosom Res 28 (1984) 411-421
70. Creed F.A., Craig T., and Farmer R.G. Functional abdominal pain, psychiatric illness and life events. Gut 29 (1988) 235-242
71. Olden K.W., and Drossman D.A. Psychologic and psychiatric aspects of gastrointestinal disease. Med Clin North Am 84 (2000) 1313-1327
72. Hveem K., Hausksen T., Svebak S., and Berstad A. Gastric antral motility in functional dyspepsia: effect of mental stress and cisapride. Scand J Gastroenterol 31 (1996) 452-457
73. Haug T.T., Wilhelmsen I., Berstad A., and Ursin H. Life events and stress in patients with functional dyspepsia compared with patients with duodenal ulcer and healthy controls. Scand J Gastroenterol 30 (1995) 524-530
74. Drossman D.A., Leserman J., Nachman G., Li Z.M., Gluck H., Toomey T.C., et al. Sexual and physical abuse in women with functional organic gastrointestinal disorders. Ann Intern Med 113 (1990) 828-833
75. Talley N.J., Felt S.L., Zinmeister A.R., and Melton III L.J. Gastrointestinal tract symptoms and self reported abuse: a population based study. Gastroenterology 107 (1994) 1040-1049
76. Drossman D.A., Li Z., Leserman J., Toomey T.C., and Hu Y.J. Health status by gastrointestinal diagnosis and abuse history. Gastroenterology 110 (1996) 999-1007
77. Leserman J., Li Z., Drossman D.A., Toomey T.C., and Hu Y.J. Impact of sexual and physical abuse dimensions on health status: development of an abuse severity measure. Psychosom Med 59 (1997) 152-160
78. Leserman J., Drossman D.A., Li Z., Toomey T.C., Nachman G., and Glogan L. Sexual and physical abuse in gastroenterology practice: how symptoms of abuse impact health status. Psychosom Med 58 (1996) 4-15
79. Blanchard E.B., Keefer L., Payne A., Turner S.M., and Galovski T. Early abuse psychiatric diagnosis and irritable bowel syndrome. Behav Results Ther 40 (2002) 289-298
80. Drossman D.A., Creed F.V., and Olden K.W. Psychological aspects of the functional gastrointestinal disorders. In: Drossman D.A., Corazziari E., Talley N.J., et al. (Eds). Rome II the functional gastrointestinal disorders: diagnosis, pathophysiology and treatment: a multinational consensus (2000), McLean V A, Degnon & Associates 157-245
81. Walker E.A., Kato W.J., Jemelka P.P., and Roy-Bryne P.P. Comorbidity of gastrointestinal complaints, depression and anxiety in the Epidemiological Catchment Area (ECA) Study. Am J Med 92 (1992) 265-305
82. Olden K.W., and Brotman A.W. Irritable bowel/irritable mood: the mind/gut connection. Harv Rev Psychiatry 6 (1998) 149-154
83. Tanum L., and Malt U.F. Personality and physical symptoms in non-psychiatric patients with functional gastrointestinal disorder. J Psychosom Res 50 (2001) 139-146
84. Jess P., and Eldrup J. The personality patterns in patients with duodenal ulcer and ulcer-like dyspepsia and their relationship to the course of the disease. J Intern Med 235 (1994) 589-594
85. Drossman D.A., McKee D.C., Sandler R.S., Mitchell C.M., Cramer E.M., Lowman B.C., et al. Psychosocial factors in the irritable bowel syndrome. Gastroenterology 95 (1988) 701-708
86. Talley N.J., Phillips S.F., Bruce B., Toomey C.K., Zinsmeister A.R., and Melton III L.J. Relation among personality and symptoms in non-ulcer dyspepsia and the irritable bowel syndrome. Gastroenterology 99 (1990) 327-333
87. Whitehead W.E., Burnette C.K., and Cook III E. Health related quality of life in IBS patients compared to IBS non-consulters and asymptomatic individuals. Am J Gastroenterol 89 (1994) 1700
88. Haug T.T., Svebak S., Wilhelmsen I., Berstad A., and Ursin H. Psychological factors and somatic symptoms in functional dyspepsia: a comparison with duodenal ulcer and healthy controls. J Psychosom Res 38 (1994) 281-291
89. Kettell J., Jones R., and Lydeard S. Reasons for consultation in irritable bowel syndrome and patient characteristics. Br J Gen Pract 42 (1992) 459-461
90. Talley N.J., Boyce P.M., and Jones M. Predictors of health care seeking for irritable bowel syndrome: a population based study. Gut 41 (1997) 394-398
91. Gomborone J., Dewsaap P., Libby G., and Farthing M. Abnormal illness attitudes in patients with irritable bowel syndrome. J Psychosom Res 39 (1995) 227-230
92. Whitehead W.E., Palsson O., and Jones K.R. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what at the causes and implications?. Gastroenterology 122 (2000) 1140-1156
93. Locke III G.R., Zinsmeister A.R., Talley N.J., Felt S.C., and Melton L.J. Familial association in adults with functional gastrointestinal disorders. Mayo Clin Prac 75 (2000) 907-912
94. Tack J., Demelts I., Denhondt G., Caenepeel P., Fischler B., Zandecki M., et al. Clinical and pathophysiological characteristics of acute onset functional dyspepsia. Gastroenterology 122 (2002) 1738-1747
95. Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological intervention for non-ulcer dyspepsia/update of Cochrane Database Systematic Reviews 2000 (2) CD001960; PMID 10796840 Cochrane Database of Systematic Reviews 2003 (1); CD001960.
96. Abraham N.S., Moayyedi P., Daniels B., and Veldhuyzen Van Zanten S.J.O. Systematic review: methodological quality of trials affects estimates of treatment efficacy in functional (non-ulcer) dyspepsia. Aliment Pharmacol Ther 19 (2004) 631-641
97. Talley N.J., and Lauritsen K. The potential role of acid suppression in functional dyspepsia: the BOND, OPERATE, PILOT and ENCORE studies. Gut 4 Suppl. (2002) iv36-iv41
98. Wong W.M., Wong B.C., Hung W.K., Yee Y.K., Yip A.W., Szeto M.L., et al. Double-blind randomised, placebo-controlled study of four weeks of lansoprazole for treatment of functional dyspepsia in Chinese patients. Gut 51 (2002) 502-506
99. Archimandritis A., Tzivras M., Fertakis A., Emmanuel A., Laoudi F., Kalantzis N., et al. Cisapride, metoclopramide and ranitidine in the treatment of severe non-ulcer dyspepsia. Clin Ther 14 (1992) 553-561
100. Jean R., Ducrot F., and Ruskone A. Symptomatic, radionuclide and therapeutic assessment of chronic idiopathic dyspepsia: a double-blind, placebo-controlled evaluation of cisapride. Dig Dis Sci 34 (1989) 657-664
101. Veldhuyze Van Zanten S.J., Jones M.J., Verlinden M., and Talley N.J. Efficacy of cisapride and domperidone in functional (non-ulcer) dyspepsia: a meta-analysis. Am J Gastroenterol 96 (2001) 689-696
102. Bytzer P., Moller Hansen J., and Schaffalittzky de Muckadell O. Treatment of non-ulcer dyspepsia: are prokinetics effective?. Scand J Gastroenterol 37 (2002) 617-620
103. Janssens J., Peeters T.L., Vantrappen G., Tack J., Urbain J.L., DeRoo M., et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin: preliminary studies. N Eng J Med 322 (1990) 1028-1031
104. Tack J., and Peeters T. What comes after macrolides and other motilin stimulants. Gut 49 (2001) 317-318
105. Piessevaux H., Tack J., Wilmer A., Coulie B., Geubel A., and Janssens J. Perception of changes in the wall tension of the proximal stomach in humans. Gut 49 (2001) 203-208
106. Moayyedi P., Soo S., Deeks J., Delaney B., Harris A., Innes M., et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Br J Med 321 (2000) 659-664
107. Malfertheiner P., Mossner J., Fischbach W., Layer P., Leodolter A., Stolte M., et al. Helicobacter pylori eradication is beneficial in treatment of functional dyspepsia. Aliment Pharmacol Ther 18 (2003) 615-625
108. Koelz H.R., Amold R., Stolte M., Fischer M., and Blum A.C. The FROSCH study group. Gut 52 (2003) 40-46
109. Gibinski K. Step by step towards the natural history of peptic ulcer disease. J Clin Gastroenterol 5 (1983) 299-302
110. Labenz J., Blum A.L., Bayerdorffer E., Meining A., Stolte M., and Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux oesophagitis. Gastroenterology 112 (1997) 1442-1447
111. Vakin N., Hahn B., and McSorley D. Recurrent symptoms and gastro-oesophageal reflux disease in patients with duodenal ulcer treated by H. pylori eradication. Aliment Pharmacol Ther 14 (2000) 45-51
112. Tack J., Coulie B., Wilmer A., Andrioli A., and Janssens J. Influence of sumatriptan on gastric fundus tone and on the perception of gastric distension in man. Gut 46 (2000) 468-473
113. Boeckxstaens G.E., Hirsch D.P., and Kuiken S.D. The proximal stomach and post prandial symptoms in functional dyspepsia. Am J Gastroenterol 97 (2002) 40-48
114. Tack J., Vos R., Janssens J., Salter J., Jauffret S., and Vanderplassche G. Influence of tegaserod on proximal gastric sensory and motor function in man. Gastroenterology 122 (2002) T1308
115. Degan L., Matzinger D., Merz M., Appel-Dingermanse S., Osborne S., Luchinger S., et al. Tegaserod a 5HT4 receptor partial agonist accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Alimen Pharmacol Ther 15 (2001) 1745-1751
116. Tack J., Delia T., and Ligozio G. A phase II placebo-controlled randomised trial with tegaserod in functional dyspepsia patients with normal gastric emptying. Gastroenterology 122 (2002) A20
117. Talley N.J., Van Zanten S.V., Saez L., Dukes G., Perschy T., Heath M., et al. A dose ranging, placebo-controlled randomised trial of alosetron in patients with functional dyspepsia. Aliment Pharmacol Ther 15 (2001) 525-537
118. Kuo B., Camilleri M., Burton D., Viramontes B., McKinzie S., Thomforde G., et al. Effects of 5HT3 antagonism on post prandial gastric volume and symptoms in humans. Aliment Pharmacol Ther 16 (2002) 225-233
119. Tack J., Piessevaux H., Coulie B., Caenepeel P., and Janssens J. A placebo controlled trial of buspirone, a fundus relaxing drug in functional dyspepsia: effect on symptoms and gastric sensory and motor function. Gastroenterology 116 (1999) B1423
120. De Ponti F. Pharmacology of serotonin: what a clinician should know. Gut 53 (2004) 1520-1535
121. Sarnelli G., Vos R., Sifrin D., Janssens J., and Tack J. Influence of sildenafil on fasting and post prandial gastric tone in man. Gastroenterology 120 (2001) 1478
122. Feinle C., Grundy D., Otto B., and Fried M. Relationship between increasing duodenal lipid doses, gastric perception and plasma hormone levels in humans. Am J Physiol Regul Integr Comp Physiol 278 (2000) R1217-R1222
123. Moran T.H. Cholecystokinin and satiety: current prospectives. Nutrition 16 (2000) 858-865
124. Reed N.W., Abitbol J.C., Badhan K., Whorwell P., and Fraitag B. Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia. Gut 41 (1997) 664-668
125. Coffin B., Bochassira D., Chollet R., Fraitag B., DeMeynard C., Geneve J., et al. Effect of the kappa agonist fedotozine on perception of gastric distension in healthy humans. Aliment Pharmacol Ther 10 (1996) 919-925
126. Delgado-Aros S., Chiel H.J., Cremonini F., Ferber I., McKinzie S., and Burton D. Effects of asimadoline, a kappa opioid agonist, on satiation and post prandial symptoms in health. Aliment Pharmacol Ther 18 (2003) 507-514
127. De Schepper H.U., Cremonini F., Park M.I., and Camilleri M. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil 16 (2004) 383-394
128. Kiuken S.D., Lei A., Tytgat G.N., Holiman R., and Boeckxstaens G.E. Effect of the low-affinity non-competitive N-methyl-d-aspartate receptor antagonist dextromethophan on visceral perception in healthy volunteers. Aliment Pharmacol Ther 16 (2002) 1955-1962
129. Chawla S.P., Grunberg S.M., Gralla R., Hesketh P.J., Rittenberg C., and Elmer M.E. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy induced nausea and vomiting. Cancer 97 (2003) 2290-2300
130. Giardina G.A., Gagliardi S., and Martinelli M. Antagonists at the neurokinin receptor, recent patient literature. Drugs 6 (2003) 758-772
131. 2 adrenergic agents in humans. Gastroenterology 116 (1999) 573-585
132. Mertz H., Walsh J.H., Sytnik B., and Mayer E.A. The effect of octreotide in human gastric compliance and sensory perception. Neurogastroenterol Motil 7 (1995) 175-188
133. Foxx-Orenstein A., Camilleri M., Stephens D., and Barton D. Effect of somatastatin analogue on gastric motor and sensory functions in healthy humans. Gut 52 (2003) 1555-1561
134. Jackson J.L., O'Malley P.G., Tomkins G., Balden E., Santoro J., and Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 108 (2000) 65-72
135. Mertz H., Fass R., Kodner A., Yan-Go F., Fullerton S., and Mayer E.A. Effect of amitriptyline on symptoms, sleep and visceral perception in patients with functional dyspepsia. Am J Gastroenterol 93 (1998) 160-164
136. Tanum L., and Malt U.F. A new pharmacologic treatment of functional gastrointestinal disorders. A double-blind placebo-controlled study with mianserin. Scand J Gastroenterol 31 (1996) 318-325
137. Gorelick A.B., Koshy S.S., and Hooper F.G. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans. Am J Physiol 275 3 Pt 1 (1998) G460-G466
138. Lancaster Smith M.J., Prout B.J., Pinto T., Anderson A., and Schiff A.A. Influence of drug treatment on the irritable bowel syndrome and its interaction with psychoneurotic morbidity. Acta Psychiatr Scand 66 (1982) 33-41
139. Tack J., Broekaert B., Couli F., Fischler B., and Janssens J. Influence of selective serotonin re-uptake inhibitor, paroxetine, on gastric sensori-motor function in humans. Aliment Pharmacol Ther 17 (2003) 603-608
140. Ladabaum U., and Gidden B. Effect of the serotonin re-uptake inhibitor sertraline on gastric sensitivity and compliance in healthy humans. Neurogastroenterol Motil 14 (2002) 395-402
141. Drossmann D.A., McKee D.C., Sandler R.S., Mitchell C.M., Cramer E.M., Lowman B.C., et al. Pyschosocial factors in the irritable bowel syndrome. A multi-variate study of patients and non-patients with irritable bowel syndrome. Gastroenterology 95 (1988) 701-708
142. Toner B.B., Garfinkle P.E., and Jeejeebhoy K.N. Psychological factors in irritable bowel syndrome. Can J Psychiatry 35 (1998) 161
143. Colgan S., Creed F.A., and Klass H. Symptomatic complaints, psychiatric disorders and abnormal illness behaviour in patients with upper abdominal pain. Psychol Med 18 (1988) 887-892
144. Bennett E.J., Piesse C., Palmer K., Badcock C.A., Tennant C.C., and Kellow J.E. Functional gastrointestinal disorders, psychological, social and somatic features. Gut 42 (1998) 414-420
145. Hamilton J., Guthrie E., Creed F., Thompson D., Tomensen B., Bennett R., et al. A randomised controlled trial of psychotherapy in patients with chronic functional dyspepsia. Gastroenterology 119 (2000) 661-669
146. Calvert E.L., Houghton L.A., Cooper P., and Whorwell P. Long term improvement in functional dyspepsia using hypnotherapy. Gastroenterology 123 (2002) 1778-1785
147. Fintelmann V. Phytopharmaka in der gastroenterologic. Z Phytother 15 (1994) 137-141
148. Ernst E. Prevalence of use of complementary alternative medicine: a systematic review. Bull WHO 78 (2000) 252-257
149. Fetrow C.W., and Avida J.R. Professionals handbook of complementary and alternative medicines (1999), Springhouse Corporation, Pennsylvania, USA
150. Madisch A., Heydereich C.J., Wieland V., Hufnagel R., and Hotz J. Treatment of functional dyspepsia with a fixed peppermint oil and caraway oil combination preparation as compared to cisapride. Arzneixmittelforschung 49 (1999) 925-932
151. May F., Kohler S., and Scheider B. Efficacy and tolerability of a fixed combination of peppermint oil and caraway oil in patients suffering from functional dyspepsia. Aliment Pharmacol Ther 14 (2000) 1671-1677
152. Holtmann G., Adam B., Haag S., Collet W., Grunewald E., and Windeck T. Efficacy of artichoke leaf extract in the treatment of patients with functional dyspepsia: a six week placebo-controlled, double-blind, multi-centre trial. Aliment Pharmacol Ther 18 (2003) 1105-1109
153. Mayer E.A., and Gebhert G.F. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 107 (1994) 271-293
154. Bortoloti M., Coccia G., Gross G., and Miglioli M. The treatment of functional dyspepsia with red pepper. Aliment Pharmacol Ther 16 (2002) 1075-1082
155. Lee K.J., Vos R., and Tack J. Effects of capsaicin on the sensori motor function of the proximal stomach in humans. Aliment Pharmacol Ther 19 (2004) 415-425
156. Thompson Coon J., and Ernst E. Systematic review: herbal medicinal products for non-ulcer dyspepsia. Aliment Pharmacol Ther 16 (2002) 1689-1699
157. Meineche-Schmidt V., and Jorgensen T. Fluctuation in dyspepsia subgroups over time. A three year follow-up of patients consulting general practice for dyspepsia. Dig Liver Dis 34 (2002) 332-338
158. Stanghellini V., Tosetti C., De Giorgio R., Barbara G., and Corinaldesi R. Dyspepsia and dyspepsia subgroups. Not all roads lead to Rome. Dig Liver Dis 34 (2002) 316-318
159. Andriulli A., Grossi E., Buscema M., Festa V., Intraligi N.M., Dominici P., et al. Contribution of artificial neural networks to the classification and treatment of patients with uninvestigated dyspepsia. Dig Liver Dis 35 (2003) 222-231
160. Marzio L., Capello G., and Ballone E. Evaluation of dyspeptic symptoms in patients with and without Helicobacter pylori infection and normal upper gastrointestinal endoscopy. Dig Liver Dis 35 (2003) 138-142
161. Perri F., Festa V., Grossi E., Garbagna N., Leandro G., and Andriulli A. Dyspepsia and Helicobacter pylori infection: a prospective multicentre observational study. Dig Liver Dis 35 (2002) 157-164
162. Sarnelli G., Vandenberghe J., and Tack J. Visceral hypersensitivity in functional disorders of the upper gastrointestinal tract. Dig Liver Dis 36 (2004) 371-376